Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Jilin Province Huinan Changlong Bio-pharmacy Company Limited Fundamental Analysis
Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK) shows moderate financial fundamentals with a PE ratio of 8.01, profit margin of 20.94%, and ROE of 8.42%. The company generates $0.7B in annual revenue with moderate year-over-year growth of 4.71%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 55.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 8049.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak8049.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent8049.HK trades at attractive valuation levels.
Growth Score
Moderate8049.HK shows steady but slowing expansion.
Financial Health Score
Excellent8049.HK maintains a strong and stable balance sheet.
Profitability Score
Weak8049.HK struggles to sustain strong margins.
Key Financial Metrics
Is 8049.HK Expensive or Cheap?
P/E Ratio
8049.HK trades at 8.01 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 8049.HK's PEG of 0.09 indicates potential undervaluation.
Price to Book
The market values Jilin Province Huinan Changlong Bio-pharmacy Company Limited at 0.66 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.07 times EBITDA. This is generally considered low.
How Well Does 8049.HK Make Money?
Net Profit Margin
For every $100 in sales, Jilin Province Huinan Changlong Bio-pharmacy Company Limited keeps $20.94 as profit after all expenses.
Operating Margin
Core operations generate 24.09 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.42 in profit for every $100 of shareholder equity.
ROA
Jilin Province Huinan Changlong Bio-pharmacy Company Limited generates $5.40 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Jilin Province Huinan Changlong Bio-pharmacy Company Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Jilin Province Huinan Changlong Bio-pharmacy Company Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
8049.HK converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
8.01
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.09
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.66
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.68
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.52
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How 8049.HK Stacks Against Its Sector Peers
| Metric | 8049.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 8.01 | 28.45 | Better (Cheaper) |
| ROE | 8.42% | 763.00% | Weak |
| Net Margin | 20.94% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.04 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.52 | 2795.60 | Neutral |
| ROA | 5.40% | -16588.00% (disorted) | Weak |
8049.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Jilin Province Huinan Changlong Bio-pharmacy Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
36.43%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
27.31%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
65.76%
Industry Style: Defensive, Growth, Innovation
High Growth